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Abstract
Preclinical animal studies have convincingly demonstrated that tumor immunity to self antigens can
be actively induced and can translate into an effective anti-tumor response. Several of these
observations are being tested in clinical trials. Immunization with xenogeneic DNA is an attractive
approach to treat cancer since it generates T cell and antibody responses. When working in
concert, these mechanisms may improve the efficacy of vaccines. The use of xenogeneic DNA in
overcoming immune tolerance has been promising not only in inbred mice with transplanted
tumors but also in outbred canines, which present with spontaneous tumors, as in the case of
human. Use of this strategy also overcomes limitations seen in other types of cancer vaccines.
Immunization against defined tumor antigens using a xenogeneic DNA vaccine is currently being
tested in early phase clinical trials for the treatment of melanoma and prostate cancers, with
proposed trials for breast cancer and Non-Hodgkin's Lymphoma.
Introduction
Since the 1990s, tumor immunology has developed into
a distinct discipline with a metamorphosis from clinical
observations in oncology to understanding its scientific
underpinnings. This has been particularly relevant to the
development of active immunotherapies (vaccines) for
cancer. Traditionally, vaccines have been effective in the
induction of protective immunity to bacteria and viruses
based on recognition of foreign, or non-self, antigens on
these pathogens. However, cancer cells arise from one's
own tissue (self) and this poses a challenge in the devel-
opment of effective active immunotherapies for cancer. It
also presents a conundrum: can the immune system
mount an effective response to reject tumors?
Perhaps the answer to the above question lies in the para-
digm that the immune system can distinguish self from
'altered self' rather than the traditional non-self [1]. While
some mutated gene products (altered self) have been
identified, surprisingly, the vast majority of antigens on
cancers characterized to date are unaltered self antigens.
These are antigens encoded by genes expressed by both
tumor cells as well as their normal cell counterparts. That
cancer immunity exists, is observed clinically in the form
of spontaneous regressions in melanoma, GI tumors, lung
and breast cancers [2]. In addition, histopathology of
tumor sections has revealed infiltrating lymphocytes
around the tumor bed and recent studies indicate that
ovarian cancer patients with such infiltrates around
tumors have an improved prognosis, compared with sim-
ilarly staged patients without lymphocytic infiltrates [3].
The immune repertoire therefore contains auto-reactive
immune cells that may reject tumors, when activated
appropriately. These auto-reactive cells, upon recognizing
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target molecules on normal cells have the potential to
induce tissue destruction leading to toxic autoimmunity.
In this article, we will outline the different types of anti-
gens and their potential use in cancer immunotherapy.
Secondly, we will summarize the data on immune
responses generated to various proteins found on
melanoma cells with an example of how differentiation
antigens can be used as immunologic targets. In this sec-
tion, we will describe the development of xenogeneic
DNA vaccines from an initial laboratory concept into
products used in human clinical trials. In the process, we
will also highlight the results from an early clinical trial
done in a new type of model with spontaneous cancer in
outbred companion animals. This development of more
predictive pre-clinical models may help to narrow the gap
between very promising results seen in inbred animals
with transplanted tumors and the relatively disappointing
results obtained to date using cancer vaccines in humans.
Tumor antigens
The molecular characterization of several tumor antigens
identified by both by T cells [4] and serology [5], has pro-
vided several candidates for the development of immuno-
therapy of various malignancies. Tumor antigens can be
broadly categorized into two types – those that are unde-
fined and others that are well defined.
Undefined antigens
Undefined and unidentified antigens are found in both
allogeneic and autologous vaccine settings described
below. Prominent examples of this type of vaccine based
on undefined antigen are intact cells, cell lysate, total
(amplified) RNA vaccines and heat-shock proteins. The
underlying principle is that relevant tumor rejection anti-
gens would be present among the thousands of other
molecules that would be injected at the same time. The
presence of unique as well as universal (or shared) tumor
antigens in the mixture would prevent the expected emer-
gence of antigen loss or escape variants. Tumors are
known to commonly downregulate or lose key molecules
to escape immune surveillance [6]. Therefore, use of vac-
cines with numerous targets that induce multiple compo-
nents of the immune response is advantageous.
Some of the earliest attempts in inducing an anti-tumor
response were seen in melanoma where intact, allogeneic
cell lines were used as a vaccine. Allogeneic tumor vac-
cines may amplify the immune response as a result of
non-specific stimulation. In addition, professional anti-
gen presenting cells (APCs) such as dendritic cells (DCs)
may phagocytose apoptotic tumor cells from the vaccine
and effectively cross prime T cells with a host of immuno-
genic epitopes [7]. Canvaxin™ (CancerVax Corporation,
CA), a whole cell vaccine, is a mixture of 3 sublethally irra-
diated, allogeneic melanoma lines, with different HLA
haplotypes expressing various known tumor antigens.
Early phase clinical trial results have shown that this vac-
cine induces both strong cellular DTH and high anti-TA90
IgM and anti GD2, GD3, GM2 and GM3 ganglioside IgM
titers in patients with resected melanoma that are associ-
ated with improved survival [8]. Serum complement
dependent cytotoxicity for melanoma cell lines in vitro
also increased over baseline levels when patients were
administered this polyvalent vaccine [9]. Having demon-
strated encouraging response rates and low toxicity in
Phase I and II trials, Canvaxin™ is presently being tested as
a postsurgical adjuvant therapy in Phase 3 trials for AJCC
stage III and IV melanoma [10], [11]. The vaccine was also
tested in a small group of colorectal carcinoma patients
with stage IV disease [12]. The rationale behind this was
that shared antigens between melanoma and colorectal
carcinoma would induce an anti-tumor response against
colon carcinoma. Indeed, DTH responses to Canvaxin™
increased significantly in 78% of these patients after treat-
ment. In addition, both IgM and IgG responses to TA90
were also elevated post treatment, with a correlation of
higher IgM titers and disease free survival.
Allogeneic cell lysate vaccines provide a similar concept
except that protein and other cellular components from
the lysate serve as the immunogens. Melacine® (Corixa
Corporation, WA) a lysate from two allogeneic melanoma
lines plus an immunological adjuvant DETOX® (Corixa
Corporation, WA) is the second type of allogeneic whole
cell vaccine. This is also used in an adjuvant setting in
resected Stage II melanoma patients [13]. Melacine has
demonstrated a modest anti-tumor activity in AJCC stage
IV melanoma, leading to licensure in Canada for use in
advanced disease [14]. Clinical activity in the adjuvant set-
ting may be more pronounced in patients expressing HLA-
A2 and/or HLA-C3, with these patients showing signifi-
cant improvements in relapse-free survival [15]. Prospec-
tive randomized trials are needed to confirm the clinical
benefit of this type of vaccine in these HLA subsets in the
adjuvant setting.
A third source of undefined tumor antigens is in the form
of total tumor RNA (sometimes amplified when tumor
availability is low) loaded onto dendritic cells (DCs), thus
allowing for endogenous expression of total protein by a
professional APC. Proof of principle was established using
defined antigens in mouse models [16]. Early clinical tri-
als using defined RNA antigens such as CEA [17] and PSA
[18] showed induction of specific cytolytic CD8+ T cell
responses. Subsequently, universal antigens such as tel-
omerase [19] and survivin were used to show specificity in
different tumor systems [20]. This idea has since evolved
into a potential therapeutic approach using total tumor
RNA, representing the entire pool of antigens. VaccinationJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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with this type of product elicited T cell responses in leuke-
mia and glioma [21], [22]. CD8+  specific reactivities
against a broad set of tumor-associated antigens, includ-
ing telomerase reverse transcriptase (TERT) were also seen
in a clinical trial performed in patients with renal cell car-
cinoma [23], [24].
Heat-shock proteins (HSPs) have recently been demon-
strated to be a means to generate an anti-tumor response
by presenting the entire antigenic blueprint to the
immune system. HSPs are expressed by cells in response
to physical, chemical and environmental stress and are
highly conserved in evolution. Immunologically, they
function as intracellular peptide carriers and the com-
plexes are taken up by DCs and macrophages to activate
CD8+ cells [25], [26], [27]. In many instances, the HSP-
peptide complexes are purified from an individual
patient's tumor, whereas an alternative approach utilizes
recombinant HSP linked to synthetic peptides [28]. Stud-
ies using HSP-peptide complexes in various early clinical
trials indicate safety but with immunologic specificity and
correlated clinical activity limited to a few patients with
melanoma and colorectal carcinoma [29], [30], [31].
A vaccine source that provides the entire antigenic reper-
toire to the immune system has several advantages, per-
haps the most important being a lack of HLA restriction
among candidate patients. The drawback, however, is that
there are only a few known tumor antigens that may be
used as targets to monitor specific immune responses dur-
ing a trial, with most of them being weak antigens. As a
result, it would be difficult to draw a correlation between
an overall immunologic response to multiple antigens
and a clinical outcome (Table 1). The search for new
markers and optimum methods to monitor immune
responses could perhaps bridge the two and help to
improve vaccine design and efficacy for the next genera-
tion of this type of vaccine.
Defined antigens
An advantage of using defined antigens for immuno-
therapy is the ability to correlate specific immune
responses with the antigen used, thus providing a means
to study and improve immunogenicity of the vaccine,
though the vaccine will have to be targeted to patients of
selected HLA types. The approach of using defined anti-
gens has been most widely explored in trials of individual
antigens though combinations have also been tested.
Using a 'cocktail' of defined antigens addresses some of
the concerns about the emergence of antigen escape
variants. These antigens can be grouped into various cate-
gories as indicated below (Table 2).
Unique antigens
Mutations in genes may create new gene products with or
without altered gene function. These can give rise to new
antigenic epitopes that may be immunogenic. Typical
examples include proto-oncogenes that are involved in
normal cell division and differentiation. A single point
mutation may activate an oncogene (e.g. ras, b-raf) or
Table 1: Advantages and disadvantages of vaccines with defined and undefined antigens
Advantages Disadvantages
Undefined Antigens 1. Availability of several potential tumor rejection antigens. 1. Difficulty in correlating clinical response and overall 
immune response based on select known antigens.
2. Unrestricted HLA patient population. 2. Largely dependent on clinical endpoint.
Defined Antigens 1. Temporal monitoring of specific immune response. 1. Limited number of known tumor antigens for use (single 
or cocktail).
2. Possibility of correlation of immune response with 
antigen expression on tumors.
2. Relatively limited targeting of patient population due to 
HLA restriction.
Table 2: Classification of defined immunogens in cancer
Antigens Examples References
Unique antigens (usually caused by mutations) p53, ras, β-catenin, CDK4, CDC27, α actinin-4 32, 34, 36, 37, 38, 39
Differentiation antigens Tyrosinase, TRP1/gp75, TRP2, gp100, Melan-A/MART1, gangliosides, PSMA 42, 43, 44, 48, 50, 51
Overexpressed antigens HER2, WT1, EphA3, EGFR, CD20 55, 59, 60, 61, 62
Cancer-testis antigens MAGE, BAGE, GAGE, NY-ESO-1 63, 64
Universal antigens Telomerase, Survivin 19, 20Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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inactivate tumor suppressor genes (CDK4, p53) causing
increased signal transduction and uncontrolled cell divi-
sion. These mutations result in proteins that are involved
in the induction of malignancy and may be important in
maintaining the malignant phenotype, making them
compelling targets for immunotherapy. Point mutations
in tumor suppressor genes such in p53 are seen in about
50% of human malignancies. Antibodies to p53 muta-
tions correlate with poor prognosis and can be associated
with either undetected malignancy or a pre-malignant
state [32]. Mutations in the ras gene occur in approxi-
mately 15% of cancers and the gene product has been
shown to induce both CD4+ and CD8+ T cell responses in
colorectal and pancreatic cancers [33], [34], [35]. In
melanoma patients, mutations in β-catenin, a protein
involved in cell adhesion and signaling regulation, result
in epitopes that induce a HLA-A*24 restricted CD8+ T cell
response [36]. Similarly, an amino acid substitution in
CDK4, a cell cycle regulator, is recognized by CD8+ T cells
[37]. A mutation in CDC27 causing altered protein traf-
ficking into the endosomal compartment was found in a
melanoma. This allows for the presentation of an MHC
class II epitope and recognition by CD4+ cells [38]. More
recently, CD8+ T cells recognizing a mutated decapeptide
of α-actinin 4 were isolated from a human lung cancer
[39]. Accumulation of α-actinin 4 in the cytoplasm causes
actin bundling which increases cellular motility and may
contribute to metastasis [40].
Differentiation antigens
Tissue specific differentiation antigens are molecules
present on tumor cells and their normal cell counterparts.
Melanoma has been an excellent model to study differen-
tiation antigens as tumor targets for immunotherapy,
given the relative restricted expression of the proteins
involved in melanin biosynthesis. The prototype of this
family of differentiation antigens is tyrosinase, the rate-
limiting enzyme in melanin synthesis. Tyrosinase Related
Protein-1 (TRP)-1/hgp75, which may have DHICA oxi-
dase activity, stabilizes tyrosinase. Serum IgG antibodies
that immunoprecipitate TRP-1 have been identified in
melanoma patients [41], suggesting that other members
in the melanin synthesis pathway may also be recognized
by the immune system. A variety of Class I and II binding
epitopes have been identified in the sequences of tyrosi-
nase, TRP-1/gp75, TRP-2 and gp100/pmel17 [42], [43],
[44]. Immune responses to these antigens are mediated by
various effector mechanisms. Tumor protection in mice in
response to TRP-1/gp75 vaccination is antibody depend-
ent, whether by passive [45] or active immunization [46],
[47]. Melan-A (MART-1), whose function is not clear, is
another melanosomal protein for which CD8+ T cells have
been identified [48]. The other group of differentiation
antigens that is overexpressed is comprised of ganglio-
sides (GM3, GM2, GD2, GD3). GD3, a representative of
this family, is a glycolipid with an extracellular carbohy-
drate moiety consisting of negatively charged sialic acid
residues, which are immunogenic. The entire molecule is
anchored into the lipid cell membrane by a hydrophobic
ceramide backbone [49]. GM2 is the most immunogenic
ganglioside with higher antibody titres correlating with
better prognosis [50].
Expression of antigen targets for active immunotherapy is
certainly not limited to melanoma cells. Other solid
tumors, such as prostate cancer have proteins that would
make reasonable vaccine targets, such as prostate specific
membrane antigen (PSMA) [51]. Prostate specific antigen
(PSA) and prostatic acid phosphatase (PAP) also form
good targets for the treatment of prostate cancer, though
expression is not restricted to this cancer [52].
Overexpressed antigens
Overexpressed antigens on cancers form attractive targets
as an immune response to tumors can be elicited while
reducing potential autoimmune attack on cells bearing
the normal copy number of genes. Her2/neu (HER2) is a
proto-oncogene which shares homology with other mem-
bers of the HER family of tyrosine kinase receptors and the
epidermal growth factor receptor [53]. The cell surface
glycoprotein is overexpressed in about 30% of breast can-
cers associated with disease aggression and poor progno-
sis [54]. HER2 expression is also seen in ovary, lung,
pancreas, prostate and colon cancers. Anti-tumor effects
of Trastuzumab (Herceptin® – a humanized monoclonal
antibody) in breast cancer are mediated by either induc-
ing apoptosis [55] or Fc receptor mediated cellular anti-
body-dependent cytotoxicity [56]. However, response to
this treatment, though encouraging, is limited to a small
percentage of advanced stage patients. In an attempt to
induce both T cell and antibody responses Foy etal [57]
showed the effectiveness of developing a deleted variant
of HER2 (dHER2). This protein lacks the transmembrane
and the kinase region of the intracellular domain (ICD),
retaining just the extracellular domain (ECD) and the car-
boxyl terminal of the autophosphorylation domain of the
ICD and is effective in generating an anti tumor response
in mice [58]. Wilm's Tumor 1 (WT1) and Ephrin receptor
(Eph3) proteins are also overepressed proteins and are
examples of targets for active immunotherapy [59], [60],
while epidermal growth factor receptor (EGFR) and CD20
are overexpressed on colorectal cancer and lymphomas
respectively and are examples of targets for passive anti-
body immunotherapy [61], [62].
Cancer testis antigens
This class of antigens is found on male germ cells and is
silent on healthy somatic cells, but expressed on a variety
of tumors. After the identification of MAGE-1 [63], which
was shown to induce a CD8+ response, several antigensJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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from related families have been identified (MAGE, BAGE,
GAGE). NY-ESO-1, unrelated to the other members men-
tioned, is also a germ cell antigen, with both Class I and II
restricted epitopes [64], [65]. With restricted expression
on normal tissues, this group of antigens would poten-
tially lead to fewer and probably less severe autoimmune
reactions.
DNA vaccines
The immunogenicity of antigens delivered via plasmid
DNA was first seen in viral studies, where cDNA encoding
an influenza viral protein generated specific cytotoxic T
cells that could protect against a live influenza viral chal-
lenge [66]. In a plasmid DNA vaccine, the gene of interest
is cloned into a bacterial expression vector having a con-
stitutively active promoter for expression of the gene
product. The plasmid can be introduced into the dermis
or muscle where it is taken up by professional antigen pre-
senting cells (APCs) such as dendritic cells (DCs) as well
as by neighboring non-APCs and can be expressed for up
to two months [67]. One of two methods of uptake is pos-
sible (Fig. 1). The first possibility is the direct transfection
of APCs by plasmid DNA [68]. Even though a relatively
small number of cells present at the vaccination site are
DCs, their enhanced potential to present and prime T cells
can make this feasible. The second mechanism underlying
the efficacy of DNA immunization is cross priming [69],
[70], [71]. The DNA transfects neighboring keratinocytes
or myocytes that transcribe and translate the antigen.
Mature antigen is made available to DCs as secreted pro-
Methods of antigen presentation that could generate an immune response after DNA immunization Figure 1
Methods of antigen presentation that could generate an immune response after DNA immunization. DNA can 
directly transfect dendritic cells (DCs) which can migrate to the draining lymph node to activate naïve T cells. Alternately, they 
can be cross primed when they uptake antigen from dying keratinocytes or myocytes. They can activate both CD8+ and CD4+ 
cells in the lymph node via Class I or Class II peptide-MHC complexes. Abbreviations – DCs dendritic cells, APC Antigen present-
ing cells, MHC Major Histocompatibility Complex, TcR T Cell Receptor Complex
DC
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tein or through apoptotic transfected cells. The antigen is
then processed and presented to naïve T cells in draining
lymph nodes.
DNA vaccines have some properties that help to overcome
obstacles encountered with the use of other types of can-
cer vaccines. Dendritic cells as APCs for peptides, proteins
or RNA are known to be effective in generating antigen
specific responses [72]. However, in a clinical setting,
autologous cellular vaccines must be custom manufac-
tured for each patient, making them cost prohibitive and
labor intensive in a large vaccine trial. Peptide vaccines,
while being simpler to manufacture, can be effective only
in association with certain HLA molecules. Consequently,
only a limited pool of patients bearing the appropriate
HLA type is eligible to receive the vaccine. Though
immune monitoring to these vaccines is more straightfor-
ward, the potential for antigen escape variants is greater,
as tumors theoretically only need to alter a single amino
acid to abolish presentation of a given epitope. Protein
vaccines, on the other hand, are not HLA restricted and
can present a variety of epitopes to activate both cell medi-
ated and humoral arms of the immune system. However,
large scale manufacturing, which includes purification,
can be a challenge.
DNA vaccines encoding full length protein can circum-
vent some of these problems while having the advantages
of purified recombinant protein. First, full length cDNA of
the gene of interest provides several potential epitopes to
stimulate both cytolytic T cells as well as an antibody
response, the latter indicating the presence of strong
helper epitopes in the gene sequence. Second, insertion of
the antigen coding sequence in a bacterial expression vec-
tor provides the vaccine with a 'built-in adjuvant' offered
by unmethylated CpG motifs [73], [74]. Third, transcrib-
ing and translating the full length protein also eliminates
the need to limit patients of a defined HLA type to be eli-
gible to receive the vaccine. The simplicity and relative
economy of producing large quantities of DNA (versus
purified recombinant protein) also makes this approach
attractive. More importantly, DNA vaccines in human tri-
als for malaria and HIV treatment have shown that they
are well tolerated and safe [75], [76], [77], [78], [79]. An
added benefit is the relative ease to design and produce
altered forms of the wild type antigen with higher biolog-
ical potency.
Murine studies to support the use of xenogeneic 
immunization
The importance of using an 'altered self' form of antigen
to induce tumor protection came from studies using
lysates of SK-MEL19, a gp75+ human melanoma cell line
[46]. When mice were immunized with human
melanoma lysate, autoantibodies that recognized mouse
gp75 were produced. Immunization with murine B16
melanoma produced no antibody response, even when
potent adjuvants were included. These studies support the
idea that ignorance or tolerance to a self protein can be
overcome by presenting sources of altered antigen (e.g.,
homologous xenogeneic protein). A similar study in a rat
Her2/neu model, showed that immunization with
human intracellular domain segment of the protein gen-
erated T cell and antibody responses specific for both rat
and human Her2/neu [80]. This indicates that despite
extensive homology between the mouse and human pro-
tein, small differences in epitopes between the two are suf-
ficient to overcome immune ignorance or tolerance.
This idea was further tested with a variety of melanosomal
differentiation antigens, starting with human TRP1/gp75
[47]. Human gp75 cDNA, expressed in a plasmid
expression vector and introduced into the epidermis via
gene gun, protected mice from a syngeneic B16 tumor
challenge primary through autoantibodies, while syn-
geneic (murine) gp75 induced no tumor immunity.
Tumor protection required Fcγ receptors (FcγR), CD4+
cells and NK1.1+ cells, but interestingly was independent
of CD8+ T cells [47]. In addition to protection from tumor
challenge, many of the mice immunized with human
gp75 DNA also developed hypopigmentation of coat, pre-
sumably through cross-recognition of endogenous gp75
on melanocytes in the mouse hair follicle. An example of
the expression plasmid containing murine tyrosinase
DNA vaccine is shown in Fig 2. This vaccine is currently
being used in a clinical trial at Memorial Sloan-Kettering
Cancer Center, New York.
In tumor protection studies using the other melanosomal
antigens, a similar requirement for the xenogeneic antigen
was noted; however, there were significant differences in
the immunologic mechanisms underlying the tumor
immunity. TRP2, another protein in the melanin synthe-
sis pathway led to a potent induction of CD8+ T cells and
required both CD4+ and CD8+ effectors for tumor protec-
tion [81]. There was no dependence on antibodies or
NK1.1+ cells in this case. Gp100, another melanosomal
protein, conferred tumor protection through CD8+ T cells,
though without a strict requirement for CD4+ help [82].
While these immunogens were effective in a prophylactic
setting, a 'treatment' model to mimic the clinical scenario
was also tested. Using TRP2 as the antigen, two models
were tested. In the first case, immunization was started 10
days after injecting live tumor intravenously [81]. In the
second case, B16 melanoma was given orthotopically in
the foot pad and then surgically excised. Immunization
with huTRP2 was then carried out in a 'minimal residual
disease' setting that is comparable to adjuvant therapy for
micrometastatic cancer. A significant decrease in theJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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development of lung metastases was noted after immuni-
zation with human TRP2 [83].
Epitope spreading was an interesting phenomenon
observed among mice immunized with huTRP2 DNA. In
some of the mice, anti-TRP2 antibodies were also specific
to gp75, a related protein [84]. Determinant spreading is
a normal feature of protective immune responses to infec-
tious agents, allowing recognition of multiple antigenic
targets [85]. While the immune system depends on diver-
sification to adequately protect against non-self, it is pos-
sible that it may also play a role in protection against
aberrant processes that are dangerous to 'self', such as can-
cer. Epitope spreading (both intermolecular and intramo-
lecular) was noted in few cases of clinical responders to
peptide vaccines in trials involving patients with
melanoma. When immunized with MART-127-35 loaded
DCs, one patient developed HLA-A*0201-restricted
responses to two additional melanoma antigens (gp100
and tyrosinase) as well as a HLA-DR4-restricted MART-1
epitope [86]. The patient's tumor was positive for MART-
1, gp100 and tyrosinase. In another instance of inter- and
intramolecular spreading, the patient (who was a
responder), was immunized with DCs loaded with HLA-
A*0201 melanoma-derived epitopes MART127–35,
gp100280–288, and tyrosinase368–376D. The patient's T cells
showed reactivity to two other HLA-A*0201-binding
epitopes (gp100209–217 and tyrosinase1–9) and four HLA-
Plasmid DNA expressing mouse tyrosinase used in clinical trials at MSKCC Figure 2
Plasmid DNA expressing mouse tyrosinase used in clinical trials at MSKCC. The full length murine tyrosinase 
cDNA was cloned into a bacterial expression vector having a kanamycin resistance cassette and operating under the host's 
constitutive CMV promoter for expression
pING/Tyrosinase (murine)
6485 bp
Tyrosinase
CMV intron A
kanamycin cassette
CMV promoter
ORI
CMV Exon 1
EcoRI (2885)
EcoRI (4867)Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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DR4 class II epitopes (MART151–73, gp10044–59, gp100615–
633, and tyrosinase56–70) [87]. Temporary regression of a
melanoma metastasis was also associated with immune
reactivity toward a cryptic epitope from the MAGE-12
gene (MAGE-12170–178), after being immunized with
gp100209–2M [88]. Spreading of immune reactivity to other
melanoma antigens in subjects with clinical response,
suggests that determinant spreading may be associated
with clinical response to immunotherapy.
In early human clinical trials for infectious diseases, DNA
vaccines have not been as potent as might have been
expected given pre-clinical mouse studies [76], [78]. Sev-
eral studies have shown the benefit of adding cytokines
such as GM-CSF (both DNA and soluble protein) to
enhance the antigen specific response, perhaps by mobi-
lizing DCs as well as enhancing expression of co-stimula-
tory molecules [89], [90], [91], [92]. DNA encoding GM-
CSF was shown to improve recruitment of DCs to the
local site of injection [89]) as well as to induce infiltration
of inflammatory and Th1 precursors cytokines [90]). Co-
immunization of full length rat neu cDNA with plasmid
DNA coding for co-stimulatory molecules such as CD80,
CD86, and CD137 in a rat transgenic mouse model
induced both antigen specific T cells and antibodies
resulting in an anti-tumor effect [92]. Local use of GM-
CSF DNA can abrogate the inconvenience of multiple
injections of soluble GM-CSF protein, while potentially
offering the same benefits.
Development of xenogeneic DNA Vaccines for use in 
canines with spontaneous cancer
As mentioned above, immunotherapies that appear
promising in pre-clinical mouse models have often led to
clinical trials with disappointing clinical and immunolog-
ical results. A study was conducted in collaboration with
the Animal Medical Center of NY, a tertiary care hospital
for pets that has an oncology clinic that sees up to 5000
visits per year. The use of outbred animals with spontane-
ously arising malignancies may overcome some of the
limitations of transplantable tumor systems in syngeneic
mice and serve as a translational bridge between standard
inbred animal models and human clinical trials.
In dogs, malignant melanoma of the oral mucosa displays
a similar natural history to human cutaneous melanoma.
This includes early invasion, a predisposition to distant
metastasis and relative resistance to standard cytotoxic
therapies. Radical surgery followed by radiation is opti-
mal therapy; however, local and distant recurrence is com-
mon and difficult to treat. An initial clinical trial using
human tyrosinase DNA in 9 dogs with metastatic
melanoma was recently completed [93]. The vaccine was
given by the same route and at the same doses that are to
be used in the human clinical trial. There has been no tox-
icity associated with the vaccination. In addition, one dog
with numerous lung metastases has had a complete clini-
cal response with disappearance of all detectable disease,
lasting over one year. The median actuarial survival for
dogs on this trial predicted by Kaplan-Meier analysis is
greater than 389 days. Although this is a small single-arm
study, this data is encouraging when considered in the
context that stage-matched historical controls had a sur-
vival of less than 90 days. Similar trials have also been
completed using murine tyrosinase and murine gp75
DNA in dogs with melanoma. Follow-up is too short at
this time to reach any clinical conclusions for these trials.
A trial of GM-CSF DNA alone or in combination with
murine tyrosinase DNA is currently underway.
Clinical trials in human using syngeneic cDNA in cancer 
therapy
In a phase 1 safety study using syngeneic cDNA to CEA,
low grade transient toxicity was observed [94]. While
CEA-specific antibodies were not observed, 4 of 17
patients showed lymphoproliferative responses to CEA
after vaccination. There was no association with objective
tumor regression and sustained declines in circulating
CEA, nor a correlation between lymproliferative response
with stable disease. In another recent clinical trial, syn-
geneic cDNA encoding gp100 was used as the vaccine. The
results did not demonstrate clinical or immunologic
responses to the vaccine [95]. Several studies have indi-
cated that syngeneic cDNA is immunogenic when used
either in prime boost regimens with recombinant viral
vectors or with the use of augmentation strategies such as
cytokines or costimulatory molecules. The presence of
slight differences in epitopes between host 'self' protein
and that encoded by xenogeneic DNA plasmid vaccine,
along with inherent bacterial unmethylated CpG motifs
may be sufficient to boost the immune response to break
tolerance to tumors.
Autoimmunity
Attempting to generate immune responses to self proteins
raises reciprocal problems of immunological tolerance
and potential autoimmune sequelae. In murine studies
using melanosomal differentiation antigens, autoim-
mune depigmentation was commonly seen [45], [46],
[81] (Fig 3). However, in trials of several immunologic
therapies for cancer, autoimmune manifestations remain
rare, despite induction of immune responses. A clinical
study in melanoma using adoptive transfer of selected
tumor reactive T cells showed that regression of metastatic
melanoma was accompanied by autoimmune
depigmentation [96]. However, effector mechanisms for
both tumor immunity and autoimmunity could be differ-
ent. Murine studies have shown that active immunization
with human gp75 induces an antibody response that
depends on activating FcγR I and/or III to reject tumor,Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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while depigmentation continued in the absence of this
receptor [47]. Likewise, studies using knockout mice indi-
cated that when TRP2 was used as the immunogen,
autoimmunity was dependent on perforin, whereas
tumor immunity proceeded in the absence of perforin
[81].
Conclusion
It is now accepted that tolerance to self antigens on cancer
cells can be overcome using active immunization strate-
gies, such as with xenogeneic DNA vaccines. The hall-
marks of a successful vaccine are judged by multiple
endpoints, with the most important one being control of
dissemination of tumor. There are several steps involved
in the generation of anti-tumor immune responses. First,
there must be efficient uptake of antigen by professional
APCs, such as Langerhans cells and DCs, followed by anti-
gen processing and migration to draining lymph nodes.
Precise antigen presentation, leading to induction and
expansion of appropriate helper and cytotoxic cells bear-
ing the cognate receptor is necessary. These effector cells
must then traffic to distant tumor sites, recognize and lyse
tumor. There should be a persistant memory pool of effec-
tors to challenge tumors bearing the same antigen that
might grow out over time. Ultimately, an adaptive
response should be generated to control antigen escape
variants. The potency of the response, once induced, must
be increased to the magnitude of that as found in infec-
tious disease settings. A break anywhere in this sequence
can give rise to disease progression. Unfortunately, this is
a frustration that is frequently encountered. Specific
immune responses to tumor antigens in vitro can be
detected in patients undergoing various immunotherapies
that do not translate to a desired clinical response. A
Autoimmune depigmention as a result of immunization with human TRP2/DCT Figure 3
Autoimmune depigmention as a result of immunization with human TRP2/DCT. Abbreviations – hTRP2 human 
tyrosinase related protein-2; mTRP2 mouse tyrosinase related protein-2
No treatment/
mTRP-2
hTRP-2Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/12
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major step forward in understanding and improving vac-
cine efficacy in cancer immunotherapy is the concordance
of clinical outcomes with appropriate, well-timed and
accurate immunologic monitoring.
The search for an active immunotherapy for cancer is
clearly not easy. The xenogeneic DNA vaccine approach is
only one among the several that has potential in treating
cancer. Research in animal models (inbred mice and out-
bred companion animals) has shown great promise for
this in the treatment of solid tumors. Based on these
results, this immunization strategy is being tested in
patients with melanoma and prostate cancers at MSKCC,
NY, with further clinical trials proposed for breast cancer
and Non-Hodgkin's Lymphoma.
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